exelixis is a biopharmaceutical company focused on developing and commercializing small molecule therapies with the potential to improve the treatment of cancer. over the past decade, we have established a broad development platform, laying the foundation for our continued efforts to bring new therapies for cancer to patients in need. our first commercial product, cometriq® (cabozantinib), received its initial regulatory approval in late 2012. we are committed to excellence in all aspects of our business and are dedicated to improving the care of, and outcomes for, patients with cancer. for more information about the company and potential job opportunities, please visit our website at www.exelixis.com.
Company profile
Ticker
EXEL
Exchange
Website
CEO
Michael M. Morrissey
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
EXELIXIS INC
SEC CIK
Corporate docs
Subsidiaries
Exelixis Patent Company, LLC • Exelixis Plant Sciences, Inc. • Exelixis U.S., LLC ...
IRS number
43257395
EXEL stock data
Latest filings (excl ownership)
10-K
2023 FY
Annual report
6 Feb 24
8-K
Exelixis Announces Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Corporate Update
6 Feb 24
8-K
Results of Operations and Financial Condition
8 Jan 24
8-K
Departure of Directors or Certain Officers
20 Dec 23
10-Q
2023 Q3
Quarterly report
1 Nov 23
8-K
Exelixis Announces Third Quarter 2023 Financial Results and Provides Corporate Update
1 Nov 23
8-K
Departure of Directors or Certain Officers
19 Sep 23
8-K
Departure of Directors or Certain Officers
23 Aug 23
10-Q
2023 Q2
Quarterly report
1 Aug 23
8-K
Exelixis Announces Second Quarter 2023 Financial Results and Provides Corporate Update
1 Aug 23
Transcripts
EXEL
Earnings call transcript
2023 Q4
6 Feb 24
EXEL
Earnings call transcript
2023 Q3
1 Nov 23
EXEL
Earnings call transcript
2023 Q2
1 Aug 23
EXEL
Earnings call transcript
2023 Q1
9 May 23
EXEL
Earnings call transcript
2022 Q4
7 Feb 23
EXEL
Earnings call transcript
2022 Q3
2 Nov 22
EXEL
Earnings call transcript
2022 Q2
10 Aug 22
EXEL
Earnings call transcript
2022 Q1
11 May 22
EXEL
Earnings call transcript
2021 Q4
18 Feb 22
EXEL
Earnings call transcript
2021 Q3
3 Nov 21
Latest ownership filings
4
Amy C. Peterson
27 Feb 24
4
Dana Aftab
27 Feb 24
4
MICHAEL MORRISSEY
27 Feb 24
4
Christopher J. Senner
27 Feb 24
4
Jeffrey Hessekiel
27 Feb 24
4
Patrick J. Haley
27 Feb 24
144
Notice of proposed sale of securities
23 Feb 24
4
DAVID EDWARD JOHNSON
22 Feb 24
4
Dana Aftab
16 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Jan 21 | Jan 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 396.86 mm | 396.86 mm | 396.86 mm | 396.86 mm | 396.86 mm | 396.86 mm |
Cash burn (monthly) | 22.54 mm | 23.33 mm | 5.86 mm | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | 127.83 mm | 132.28 mm | 33.24 mm | n/a | n/a | n/a |
Cash remaining | 269.03 mm | 264.58 mm | 363.62 mm | n/a | n/a | n/a |
Runway (months of cash) | 11.9 | 11.3 | 62.0 | n/a | n/a | n/a |
Institutional ownership, Q3 2023
94.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 388 |
Opened positions | 55 |
Closed positions | 36 |
Increased positions | 131 |
Reduced positions | 147 |
13F shares | Current |
---|---|
Total value | 5.68 tn |
Total shares | 285.75 mm |
Total puts | 1.82 mm |
Total calls | 4.55 mm |
Total put/call ratio | 0.4 |
Largest owners | Shares | Value |
---|---|---|
BLK Blackrock | 37.03 mm | $809.00 bn |
Vanguard | 32.07 mm | $700.76 bn |
Farallon Capital Management | 25.86 mm | $565.04 bn |
Farallon Capital Partners | 24.91 mm | $480.35 mm |
Renaissance Technologies | 15.22 mm | $332.50 bn |
STT State Street | 12.38 mm | $270.52 bn |
JPM JPMorgan Chase & Co. | 7.65 mm | $167.11 bn |
Geode Capital Management | 5.07 mm | $110.90 bn |
Dimensional Fund Advisors | 4.59 mm | $100.38 bn |
T. Rowe Price | 4.47 mm | $97.73 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
23 Feb 24 | Amy C. Peterson | Common Stock | Grant | Acquire A | No | No | 0 | 82,121 | 0.00 | 322,121 |
23 Feb 24 | Dana Aftab | Common Stock | Grant | Acquire A | No | No | 0 | 63,350 | 0.00 | 542,381 |
23 Feb 24 | Michael Morrissey | Common Stock | Grant | Acquire A | No | No | 0 | 241,670 | 0.00 | 1,038,327 |
23 Feb 24 | Senner Christopher J. | Common Stock | Grant | Acquire A | No | No | 0 | 82,121 | 0.00 | 751,990 |
23 Feb 24 | Hessekiel Jeffrey | Common Stock | Grant | Acquire A | No | No | 0 | 63,350 | 0.00 | 655,052 |
News
Around $4M Bet On This Healthcare Stock? Check Out These 4 Stocks Insiders Are Buying
23 Feb 24
RBC Capital Maintains Outperform on Exelixis, Raises Price Target to $28
7 Feb 24
Recap: Exelixis Q4 Earnings
6 Feb 24
Exelixis Q4 Adj EPS $0.33 Beats $0.22 Estimate, Sales $479.65M Miss $484.88M Estimate
6 Feb 24
Earnings Scheduled For February 6, 2024
6 Feb 24
Press releases
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in March
27 Feb 24
Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies
14 Feb 24
Exelixis Announces Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Corporate Update
6 Feb 24
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in February
1 Feb 24
Exelixis Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Presented at ASCO GU 2024
25 Jan 24